Clovis gains on 4Q increase in Rubraca sales

Clovis Oncology Inc. (NASDAQ:CLVS) reported $30.4 million in 4Q18 revenue, all from U.S. sales of Rubraca rucaparib, up 78% from $17 million in 4Q17 and beating the consensus estimate

Read the full 299 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE